It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Type 2 diabetes and obesity are well-studied metabolic diseases, which are based on genetic and epigenetic alterations in combination with an obesogenic lifestyle. The aim of this study was to test whether SNPs in miRNA-mRNA binding sites that potentially disrupt binding, elevate the expression of miRNA targets, which participate in the development of metabolic diseases. A computational approach was developed that integrates transcriptomics, linkage analysis, miRNA-target prediction data, and sequence information of a mouse model of obesity and diabetes. A statistical analysis demonstrated a significant enrichment of 566 genes for a location in obesity- and diabetes-related QTL. They are expressed at higher levels in metabolically relevant tissues presumably due to altered miRNA-mRNA binding sites. Of these, 51 genes harbor conserved and impaired miRNA-mRNA-interactions in human. Among these, 38 genes have been associated to metabolic diseases according to the phenotypes of corresponding knockout mice or other results described in the literature. The remaining 13 genes (e.g. Jrk, Megf9, Slfn8 and Tmem132e) could be interesting candidates and will be investigated in the future.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 German Institute of Human Nutrition Potsdam-Rehbruecke, Department of Experimental Diabetology, Nuthetal, Germany (GRID:grid.418213.d) (ISNI:0000 0004 0390 0098); German Center for Diabetes Research (DZD), München, Germany (GRID:grid.452622.5)
2 Clinic for Angiology and Diabetology, Frankfurt (Oder), Germany (GRID:grid.452622.5); University of Potsdam, Institute of Nutritional Sciences, Nuthetal, Germany (GRID:grid.11348.3f) (ISNI:0000 0001 0942 1117)
3 Max Planck Institute of Molecular Plant Physiology, Am Mühlenberg 1, Potsdam, Germany (GRID:grid.418390.7) (ISNI:0000 0004 0491 976X)
4 German Institute of Human Nutrition Potsdam-Rehbruecke, Department of Experimental Diabetology, Nuthetal, Germany (GRID:grid.418213.d) (ISNI:0000 0004 0390 0098); German Center for Diabetes Research (DZD), München, Germany (GRID:grid.452622.5); University of Potsdam, Institute of Nutritional Sciences, Nuthetal, Germany (GRID:grid.11348.3f) (ISNI:0000 0001 0942 1117); Faculty of Health Sciences, joint Faculty of the Brandenburg University of Technology Cottbus – Senftenberg, the Brandenburg Medical School Theodor Fontane and the University of Potsdam, Potsdam, Germany (GRID:grid.11348.3f) (ISNI:0000 0001 0942 1117)